| 초록 |
To overcome the low therapeutic efficiency of single chemotherapy, nanotechnology-mediated combination therapies, especially combinations of siRNAs and chemotherapeutics such as paclitaxel (PTX), are promising alternatives for cancer therapy. However, some limitations, such as low delivery efficiency and therapeutic efficacy need to be overcome to achieve the enhanced efficacy. In addition, the co-delivery of siRNAs and chemotherapeutics with different physicochemical properties remains challenging. Here, high intensity focused ultrasound (HIFU)-responsive nanocomplexes, referred to as siRNA-NP-PTX-MBs, were developed to address these limitations. These nanocomplexes were capable of co-delivering siRNA and PTX. We showed that these nanocomplexes could co-deliver drugs deep into the tumor, due to the ability to penetrate the dense extracellular matrix via the sonoporation under the exposure of HIFU, resulting in both enhanced RNA interference and chemotherapeutic effects. |
